JapanStake
Pharmaceutical · Fiscal year end Mar 31

Immuno-Biological Laboratories Co., Ltd.

4570

株式会社免疫生物研究所

FIGI BBG000QWHCP84570.T4570 JPCorp. no. 8070001009687

Latest half-year results

First half · fiscal year to 2026-03 · filed 2025-11-14

For the first half of the fiscal year to 2026-03: Revenue ¥0.5 billion (+9.3% YoY), Ordinary income ¥0.1 billion (+133.4% YoY), Net income ¥0.1 billion (+98.0% YoY).

This periodYear on year
Revenue¥485m+9.3%
Ordinary profit¥150m+133.4%
Net profit to owners¥142m+98.0%

From the securities report on EDINET, which states no forecast. History via /v1/companies/4570/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2026-03-31
Revenue
¥1.0bn
Net income
¥329m
ROE
19.6%
Equity ratio
85.5%
Dividend / share
¥6
Employees
54
Revenue · ¥bn
FY2022: ¥0.6bn 0.65 FY2022FY2023: ¥0.8bn 0.79 FY2023FY2024: ¥0.8bn 0.82 FY2024FY2025: ¥1.0bn 0.97 FY2025FY2026: ¥1.0bn 1 FY2026
Net income · ¥m
FY2022: −¥259m -259 FY2022FY2023: −¥290m -290 FY2023FY2024: ¥187m 187 FY2024FY2025: ¥249m 249 FY2025FY2026: ¥329m 329 FY2026
Fiscal yearRevenueNet incomeTotal assetsNet assetsROEEPSOperating CF
2026-03-31¥1,005m¥329m¥2,155m¥1,843m19.6%¥35.33¥301m
2025-03-31¥970m¥249m¥1,845m¥1,514m17.9%¥26.74¥183m
2024-03-31¥817m¥187m¥1,619m¥1,265m15.9%¥20.05¥134m
2023-03-31¥795m−¥290m¥1,434m¥1,079m—¥-31.1¥26m
2022-03-31¥648m−¥259m¥1,705m¥1,368m—¥-27.78−¥93m

Indicators

Computed by us from filings · fiscal year to 2026-03-31
MetricValuePercentile among listed companies
ROE, %19.687.2
Ordinary margin0.299196.6
Equity ratio, %85.595.4
Revenue growth0.036643.4
Net income growth0.321166.6
Operating cash flow / assets0.139787.4
Policy-uncertainty measure0.00 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.
Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change −6.17pt in 90 days; 2.8% held by other listed companies.

Results wording balance: +1.00. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥177m of reported debt repriced by 50 basis points, a year's interest would rise by ¥1m, 0.3% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/4570/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them
Internal control, 2026-06-26: see filing 上記の評価の結果、当事業年度末日時点において、当社グループの財務報告に係る内部統制は有効であると判断した。 Filing

Segments, votes and tender offers

Stated in EDINET filings
Segments: Immunity Related, Cosmetics. /v1/companies/4570/segments
Latest voting result: 2026-06-25 · 剰余金処分の件 · passed. /v1/companies/4570/voting

Ownership changes

All companies →
  • 2026-09-30
    Decrease−2.91pt

    individual filer reduced holdings in Immuno-Biological Laboratories Co., Ltd. (4570) to 15.32% from 18.23%.

    01020304050
    S100Z57VOriginal filing (PDF, Japanese)
  • 2026-09-30
    Decrease−0.17pt

    individual filer reduced holdings in Immuno-Biological Laboratories Co., Ltd. (4570) to 15.15% from 15.32%.

    01020304050
    S100Z587Original filing (PDF, Japanese)
  • 2026-09-30
    Decrease−1.67pt

    individual filer reduced holdings in Immuno-Biological Laboratories Co., Ltd. (4570) to 13.48% from 15.15%.

    01020304050
    S100Z58ZOriginal filing (PDF, Japanese)
  • 2026-09-30
    Decrease−0.13pt

    individual filer reduced holdings in Immuno-Biological Laboratories Co., Ltd. (4570) to 13.35% from 13.48%.

    01020304050
    S100Z5A3Original filing (PDF, Japanese)
  • 2026-09-30
    Decrease−0.47pt

    individual filer reduced holdings in Immuno-Biological Laboratories Co., Ltd. (4570) to 12.88% from 13.35%.

    01020304050
    S100Z5AOOriginal filing (PDF, Japanese)
  • 2026-09-30
    Decrease−0.82pt

    individual filer reduced holdings in Immuno-Biological Laboratories Co., Ltd. (4570) to 12.06% from 12.88%.

    01020304050
    S100Z5AYOriginal filing (PDF, Japanese)
  • 2021-12-22
    Decrease−5.36pt

    Whiz Partners Inc. reduced holdings in Immuno-Biological Laboratories Co., Ltd. (4570) to 5.77% from 11.13%.

    01020304050
    S100N3M8Filer profileOriginal filing (PDF, Japanese)
  • 2021-12-22
    Threshold

    Holdings of Whiz Partners Inc. in Immuno-Biological Laboratories Co., Ltd. (4570) moved below 10% (11.13% -> 5.77%).

    01020304050
    S100N3M8Filer profileOriginal filing (PDF, Japanese)
  • 2021-12-22
    Below 5%−5.77pt

    Whiz Partners Inc. cut holdings in Immuno-Biological Laboratories Co., Ltd. (4570) to 0.00% from 5.77%, below the 5% threshold.

    01020304050
    S100N3MQFiler profileOriginal filing (PDF, Japanese)

Trades by 5% holders

From the 60-day trade tables in 5% reports
HolderPeriodNet sharesNet % of sharesAvg. filed priceRange
株式会社ウィズ・パートナーズ2021-12-17 – 2021-12-1900.00pt——

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4570/trades.

5% filings

Large shareholding reports on 4570
FiledFilerStakeChangeStated purpose
2026-09-30individual filer15.32%−2.91pt—
2026-09-30individual filer15.15%−0.17pt—
2026-09-30individual filer15.15%0.00pt—
2026-09-30individual filer13.48%−1.67pt—
2026-09-30individual filer13.48%0.00pt—
2026-09-30individual filer13.35%−0.13pt—
2026-09-30individual filer12.88%−0.47pt—
2026-09-30individual filer12.88%0.00pt—
2026-09-30individual filer12.06%−0.82pt—
2026-09-30individual filer12.06%0.00pt—

Cross-shareholdings

From the annual report's status of shareholdings
Listed strategic holdings
— issues
Book value
—
Sold in the year
— — issues
Bought in the year
— — issues
Mutual, both reports
0
Held by listed cos.
2

Held by: TRANS GENIC GROUP INC. 2342, THE TOWA BANK,LTD. 8558

Purposes, all holdings and mutual flags via /v1/companies/4570/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31
ShareholderSharesRatio
individual holder1,123,70012.07%
楽天証券株式会社共有口253,3002.72%
株式会社トランスジェニックグループ160,0001.72%
individual holder101,6001.09%
株式会社東和銀行100,0001.07%
individual holder95,0001.02%
individual holder82,5000.89%
individual holder70,0000.75%
野村證券株式会社63,1000.68%
NOMURA INTERNATIONAL PLC A/C JAPAN FLOW62,5000.67%

Get this as JSON

GET /v1/companies/4570
GET /v1/companies/4570/financials
GET /v1/companies/4570/details
GET /v1/companies/4570/segments
GET /v1/companies/4570/voting
GET /v1/companies/4570/tender-offers
GET /v1/companies/4570/indicators
GET /v1/companies/4570/earnings-releases
GET /v1/events?ticker=4570
GET /v1/companies/4570/trades         
GET /v1/companies/4570/cross-holdings 
GET /v1/companies/4570/brief

Plans from $9 a month · Documentation